These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16445306)

  • 1. Economic evaluation of rivastigmine in patients with Parkinson's disease dementia.
    Willan AR; Goeree R; Pullenayegum EM; McBurney C; Blackhouse G
    Pharmacoeconomics; 2006; 24(1):93-106. PubMed ID: 16445306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
    Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
    Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
    Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.
    Oertel W; Poewe W; Wolters E; De Deyn PP; Emre M; Kirsch C; Hsu C; Tekin S; Lane R
    Drug Saf; 2008; 31(1):79-94. PubMed ID: 18095748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine: in Parkinson's disease dementia.
    Siddiqui MA; Wagstaff AJ
    CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
    Emre M; Poewe W; De Deyn PP; Barone P; Kulisevsky J; Pourcher E; van Laar T; Storch A; Micheli F; Burn D; Durif F; Pahwa R; Callegari F; Tenenbaum N; Strohmaier C
    Clin Neuropharmacol; 2014; 37(1):9-16. PubMed ID: 24434526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
    Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
    Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia.
    Schmitt FA; Farlow MR; Meng X; Tekin S; Olin JT
    CNS Neurosci Ther; 2010 Dec; 16(6):330-6. PubMed ID: 20950329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
    Wesnes K
    Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine in Parkinson's disease dementia: profile report.
    Siddiqui MA; Wagstaff AJ
    Drugs Aging; 2007; 24(3):255-9. PubMed ID: 17362052
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.